Paradromics implants first long-term brain chip in FDA speech-restoration study

Paradromics, an Austin-based neurotechnology company, has implanted its Connexus brain-computer interface in the first participant of its FDA-approved clinical study, marking a milestone in the company's nearly decade-long effort to restore speech for people with severe motor impairments.

The surgery was performed at University of Michigan Health on a woman who lost the ability to speak clearly due to motor neuron disease, according to The Next Web. The patient will be followed for six years as part of the Connect-One Early Feasibility Study, which received FDA investigational device exemption approval in late 2025.nature+2

From Research to Clinical Reality

This is Paradromics' first chronic implant — designed to remain in the patient permanently — distinguishing it from the company's earlier brief procedure in May 2025, when the Connexus device was temporarily implanted and removed in about 20 minutes during an epilepsy surgery at the same university. That initial procedure demonstrated the system could be safely implanted and record neural signals but was not intended for long-term use.cnbc+1

The Connexus device, smaller than a dime and equipped with 420 electrodes, sits on the brain's surface and records neural activity from the speech motor cortex. When the patient attempts to speak, the implant captures the associated brain signals and software translates them into text or synthesized speech on a computer.upi+2

A Crowded Field

Paradromics is the first company to receive FDA approval for a fully implantable BCI specifically intended to restore speech, according to the company's announcement. The distinction matters in an increasingly competitive landscape that includes Neuralink, which implanted its first human patient in January 2024, and Synchron, which has pursued a less invasive approach through blood vessels.paradromics+1

The Connect-One study will evaluate both long-term safety and the device's ability to enable communication via text or synthesized speech for people living with ALS, stroke, or other conditions causing severe paralysis. Paradromics said it has also been accepted into the FDA's Total Product Life Cycle Advisory Program, a regulatory accelerator for innovative devices.paradromics+2

What Comes Next

Meaningful results from the implant will emerge over months and years rather than days, as The Next Web noted. The company has previously described ambitions beyond therapy, including direct AI interaction and advanced prosthetics, though those applications remain far in the future. For now, the focus is on proving the device works safely in its first patient — and eventually expanding enrollment to additional participants at clinical sites across the United States.paradromics+2